Latest News
GeneLancet Biosciences Inc. has appointed Leonid Beigelman, Ph.D., Scott Strobel, Ph.D....
GeneLancet_SAB_News_Release DOYLESTWON, PA, January 31, 2024 - GeneLancet Biosciences Inc. has appointed Leonid Beigelman, Ph.D., Scott Strobel, Ph.D. and Ju-Tao Guo, M.D. to its scientific advisory board
Read More ›
GeneLancet presented at 2023 26th ASGCT annual meeting.
GeneLancet presented at 2023 26th ASGCT annual meeting. We reported the progress of our anti-HBV gene editing program (Poster # 511). CRISPR-Cas9/LgRNA eliminated ~99% of both HBsAg and HBeAg in single transfection in cell models. Also reported was
Read More ›
GeneLancet Biosciences Inc. announces its receipt of additional grant support by...
DOYLESTWON, PA, January 31, 2024 - GeneLancet Biosciences Inc. ("GeneLancet "), an early-stage genome editing company, is pleased to announce its receipt of additional grant support by NIH (R21). The grant will support GeneLancet’s goal to
Read More ›
GeneLancet Biosciences Announces Phase 1 SBIR Award from National Institute of...
Doylestown, April 6, 2023 - GeneLancet Biosciences, a pre-clinical stage biotech company focused on LgRNA-guided CRISPR gene editing therapeutics for cure has been awarded a Phase I grant from the National Institute of Health. GeneLancet
Read More ›